PricewaterhouseCoopers: Government, health leaders seek customer-centric healthcare solutions
NEW YORK A new report by PricewaterhouseCoopers’ Health Research Institute found that customer-centric care solutions should be at the forefront of health care in order to improve patient well-being and drive down related costs.
“HealthCast: The customization of diagnosis, care and cure” analyzed nearly 600 government and health leaders in 20 countries, including 50 health leaders in the United States. Among the findings, PricewaterhouseCoopers discovered:
- A consensus that individuals have the greatest influence on their own health status, but that physicians have the greatest external influence on changing patient behavior
- Ninety-seven percent agreed that patients should have some responsibility for managing their chronic conditions such as obesity, asthma, diabetes and heart disease. Of those, 76% of U.S. health leaders and 57% of global leaders think patients should have a “great deal” of responsibility in this
- Eighty-two percent of U.S. health leaders and nearly three-quarters of global health leaders (74%) believe that unhealthy behavior will become increasingly unacceptable in their country
- Lack of willpower was cited as the biggest barrier keeping individuals from managing their own health.
The analysis concluded that the departmentalized thinking of health leaders and physicians has impeded patients’ health. The report suggested more focus on allowing people to play an active role in their own health.
“Through incentives baked into our health system, many health organizations have been too siloed in their thinking. They’ve focused on their silo rather than the whole continuum of care and patient engagement. If patients are not engaged, it is impossible to adequately manage care, consumption and spending.” said Kelly A. Barnes, U.S. health industries leader, PricewaterhouseCoopers. “The overarching challenge for our health system will be to shift the internal focus from the siloed bureaucratic healthcare infrastructure that exists today to one that puts patients at the center of care and engages them to take charge of their health over their entire lifetime.”
Warner Chilcott, Sanofi-Aventis clarify Actonel partnership
ARDEE, Ireland Warner Chilcott will take full control over the promotion, marketing and research-and-development decisions for an osteoporosis drug in the United States under an amendment to an agreement with French drug maker Sanofi-Aventis, Warner Chilcott announced Monday.
The earlier version of the agreement, for the drug Actonel (risendronate sodium), allowed Warner Chilcott to share the costs with Sanofi in the United States.
The agreement between the two companies expires at the end of 2014.
“The amendment to the collaboration agreement will enable Warner Chilcott to assume full control over the promotion and marketing of the Actonel brand in the United States,” Warner Chilcott president and CEO Roger Boissonneault said. “This will allow us to adjust our promotional plans in the U.S. as we prepare for the potential launch of the next-generation Actonel product.”
FDA seizes drugs from Beehive Botanicals
SILVER SPRING, Md. Federal government officials seized “dozens” of products from a company they said had been warned about misstating its medical benefits.
The Food and Drug Administration announced Monday that U.S. Marshals seized products including creams, capsules, tablets, gum, throat spray and shampoos from Haywood, Wis.-based Beehive Botanicals.
According to the FDA, the company misbranded the products by promoting them on its Web site as capable of preventing and curing diseases such as asthma, dermatitis, ulcers, cancer and others. The agency said that the claims meant the products were drugs and were thus subject to FDA regulation, but that Beehive had continued marketing them as medically beneficial despite not subjecting them to clinical trials.
“This seizure shows that the FDA will seek enforcement action against companies that promote therapeutic benefits of products not yet evaluated by the agency for safety and effectiveness,” FDA acting associate commissioner for regulatory affairs Michael Chappell said in a statement.
The FDA originally warned Beehive in March 2007 not to make drug claims on its Web site and products, and the company originally complied, but during inspections in September and October 2009, the agency said it found the company still was making inaccurate drug claims.